Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arjan van de Loosdrecht

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Cytometry. Part B, Clinical Cytometry|November 23, 2022
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working groupWolfgang Kern, Theresia M Westers, Frauke Bellos, et al.
Archives of Pathology & Laboratory Medicine|March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/NeoplasmsSavanah D Gisriel, Fnu Aakash, John M Bennett, et al.
Haematologica|July 7, 2019
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registryMarlijn Hoeks, Ge Yu, Saskia Langemeijer, et al.
Hemasphere|January 24, 2025
Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromesDavid Rombaut, Sarah Sandmann, Tobias Tekath, et al.
Cytometry. Part B, Clinical Cytometry|December 11, 2021
Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNetVincent H J van der Velden, Frank Preijers, Ulrika Johansson, et al.
Cancers|February 10, 2021
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDSJeroen Janssen, Bob Löwenberg, Markus Manz, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cytometry. Part B, Clinical Cytometry|November 23, 2022
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working groupWolfgang Kern, Theresia M Westers, Frauke Bellos, et al.
Archives of Pathology & Laboratory Medicine|March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/NeoplasmsSavanah D Gisriel, Fnu Aakash, John M Bennett, et al.
Haematologica|July 7, 2019
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registryMarlijn Hoeks, Ge Yu, Saskia Langemeijer, et al.
Hemasphere|January 24, 2025
Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromesDavid Rombaut, Sarah Sandmann, Tobias Tekath, et al.
Cytometry. Part B, Clinical Cytometry|December 11, 2021
Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNetVincent H J van der Velden, Frank Preijers, Ulrika Johansson, et al.
Cancers|February 10, 2021
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDSJeroen Janssen, Bob Löwenberg, Markus Manz, et al.
Pageof 2